Century Therapeutics, Inc. Operating Income Loss

• Century Therapeutics, Inc. showed an increase of +87.5% in Operating Income Loss from 2024 to 2025.
• This data is from Century Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
• XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 6 years of available data (2020 to 2025), Century Therapeutics, Inc.'s Operating Income Loss has grown by 68.0%.
• Historical annual values: Fiscal year 2025: -$17.27 million | Fiscal year 2024: -$138.14 million | Fiscal year 2023: -$146.55 million | Fiscal year 2022: -$133.83 million | Fiscal year 2021: -$94.88 million | Fiscal year 2020: -$53.90 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026